Table 1 Overview of demographic and treatment related variables between groups
Paraaortic lymph node metastasis positive (PALN+) (N = 19) | Paraaortic lymph node metastasis negative (PALN-) (N = 139) | Explored only (EXP) (N = 424) | p-value* | ||
|---|---|---|---|---|---|
Sex | Male (n,%) | 11 (57.9%) | 64 (46.0%) | 239 (56.4%) | 0.99 |
Female (n,%) | 8 (42.1%) | 75 (54.0%) | 185 (43.6%) | ||
Age | Median [Q1,Q3] | 67.0 [57.2,73.6] | 70.9 [61.2,76.3] | 70.1 [63.4,76.0] | 0.28 |
Charlson Comorbidity Index | Median [Q1,Q3] | 1.00 [0,2.50] | 1.00 [0,2.00] | 1.00 [0,2.00] | 0.47 |
Preoperative Chemotherapy | Yes (n,%) | 2 (10.5%) | 27 (19.4%) | 66 (15.6%) | 0.99 |
Postoperative Chemotherapy | Yes (n,%) | 15 (78.9%) | 113 (81.3%) | 290 (68.4%) | 0.99 |
Type of resection | Total Pancreatectomy (n,%) | 6 (31.6%) | 31 (22.3%) | 1 (0.2%) | 0.99 |
Pancreaticoduodenectomy (n,%) | 11 (57.9%) | 95 (68.3%) | 3 (0.7%) | ||
Missing (n,%) | 2 (10.5%) | 13 (9.4%) | 420 (99.1%) | ||
Pathology T stage | T1(n,%) | 1 (5.3%) | 13 (9.4%) | 0 (0%) | 0.99 |
T2 (n,%) | 8 (42.1%) | 46 (33.1%) | 1 (0.2%) | ||
T3 (n,%) | 8 (42.1%) | 53 (38.1%) | 1 (0.2%) | ||
T4 (n,%) | 0 (0%) | 2 (1.4%) | 0 (0%) | ||
Missing (n,%) | 2 (10.5%) | 25 (18.0%) | 422 (99.5%) | ||
Pathology N stage | N0 (n,%) | 0 (0%) | 33 (23.7%) | 1 (0.2%) | 0.99 |
N1 (n,%) | 4 (21.1%) | 52 (37.4%) | 1 (0.2%) | ||
N2 (n,%) | 13 (68.4%) | 31 (22.3%) | 0 (0%) | ||
Missing (n,%) | 2 (10.5%) | 23 (16.5%) | 422 (99.5%) | ||
Resection Margin | R0 (n,%) | 15 (78.9%) | 102 (73.4%) | 1 (0.2%) | 0.99 |
R1 (n,%) | 2 (10.5%) | 8 (5.8%) | 0 (0%) | ||
R2 (n,%) | 0 (0%) | 3 (2.2%) | 0 (0%) | ||
Missing (n,%) | 2 (10.5%) | 26 (18.7%) | 423 (99.8%) | ||
Survival status on end of follow-up | Alive | 7 (36.8%) | 74 (53.2%) | 30 (7.1%) | |
Dead | 12 (63.2%) | 65 (46.8%) | 394 (92.9%) | ||
Follow-up Time (months) | Median [Q1,Q3] | 16.5 [11.0,26.3] | 23.5 [15.1,33.6] | 11.4 [6.35,18.3] |